Fungal infections coccidioidomycosis

Miconazole is indicated in the treatment of the following severe systemic fungal infections coccidioidomycosis, candidiasis, cryptococcosis, pseudoallescheriosis (petrielMo-sis, allescheriosis), paracoccidioidomycosis, and in the treatment of chronic mucocutaneous candidiasis. 

Fungal (histoplasmosis, coccidioidomycosis, cryptococcosis, Blastomyces dermatitidis infection)... 

Indications Treatment of the following systemic fungal infections Candidiasis Chronic mucocutaneous candidiasis Oral thrush Candiduria Blastomycosis Coccidioidomycosis Histoplasmosis Chromomycosis Paracoccidioidomycosis... 

Clinical Use. Ketoconazole (Nizoral) is used to treat a variety of superficial and deep fungal infections.9,35,72 This drug can be administered orally to treat pulmonary and systemic infections in candidiasis, coccidioidomycosis, histoplasmosis, and several other types of deep fungal infections. Oral administration is... 

Parenteral amphotericin B is indicated for the trcatmeot of severe, potentially life-threatening fungal infections, including dis.seminated forms of coccidioidomycosis and histoplasmosis. sporotrichosis. North American blastomycosb, cryptococcosis, mucormycosis, and aspergillosis. 

Fungal infections have emerged as a major cause of death among cancer patients and transplant recipients. In addition, patients with acquired immune-deficiency syndrome (AIDS) experience substantially more frequent and severe forms of cryptococcosis, histoplasmosis, coccidioidomycosis, and mucocutaneous (esophageal, oral, and vulvovaginal) candidiasis. 

Therapy for coccidioidomycosis is difficult, and the results are unpredictable. Guidelines are available for treatment of this disease however, optimal treatment for many forms of this disease still generates debate. The efficacy of antifungal therapy for coccidioidomycosis is often less certain than that for other fungal etiologies, such as blastomycosis, histoplasmosis, or cryptococcus, even when in vitro susceptibilities and the sites of infections are similar. The refractoriness of coccidioidomycosis may relate to the ability of C. immitis spherules to release hundreds of endospores, maximally challenging host defensesFortunately, only approximately 5% of infected patients require therapy. ... 

Ketoconazole (KC) as the first systemlcally-active azole antifungal has been the subject of a number of reviews including the general management of fungal disease,and its efficacy in superficial and systemic infections 0 it was the subject of a number of papers at a recent symposium, The use of KC in the treatment of coccidioidomycosis has been recently reviewed in detail, 2 gjid parallel reviews of the indications for coccidioidomycosis treatment in general, 5 and the use of AMB and miconazole (MC) 5 in particular have been presented. 

---